Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi

• Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- "We are excited by this strategic investment from Sanofi, one of the world's leading biopharmaceutical companies, for our research and development programs," said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. "We view Sanofi's investment in Vigil as a validation of our promising precision medicine approach led by our two differentiated TREM2 modalities, iluzanebart and VG3927 ...